Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Commentary

A new paradigm of quality of care in rheumatoid arthritis: how our new therapeutics have changed the game

Sonali P Desai1* and Daniel H Solomon2

Author Affiliations

1 Division of Rheumatology, Immunology, and Allergy, Brigham & Women?s Hospital, 75 Francis Street, PBB-B3, Boston, MA 02115, USA

2 Division of Pharmacoepidemiology, Brigham & Women?s Hospital, 75 Francis Street, PBB-B3, Boston, MA 02115, USA

For all author emails, please log on.

Arthritis Research & Therapy 2013, 15:121  doi:10.1186/ar4356

Published: 29 October 2013

Abstract

Demonstrating the effectiveness of expensive new rheumatoid arthritis (RA) therapeutics is imperative to determine whether the quality of care has improved with the introduction of these agents. Our current RA quality measures are primarily process based, but they must become outcomes based to better demonstrate quality. New RA quality measures must be multidimensional, accounting for all of the important outcomes in RA: radiographic, functional status, and disease activity. To fully understand the potential benefits of new therapeutics in RA, outcome measures must be integrated with routine practice.